(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

Inclusion Criteria: * Subject is between 25 and 70 years of age (inclusive) at the time of randomization. * Subject is an appropriate candidate for H.E.L.P. apheresis treatment for hypercholesterolemia according to current Plasmat® Secura approval criteria. * Subject has received a minimum of two consecutive bi-monthly\* H.E.L.P. apheresis treatments using the Plasmat® Secura apheresis system \>30 days prior to the screening visit. * Subject is willing to maintain cholesterol lowering dietary and drug therapies as prescribed through the course of the study. * Subject is willing and able to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) Waiver. * Sterile, post-menopausal, or using acceptable birth control for the duration of the study. Acceptable birth control is defined as having a vasectomized, postmenopausal, or sterile partner; the ongoing use of approved hormonal contraceptives, barrier method, or an intrauterine device; or abstinence. * Every 14 days (±2 days) Exclusion Criteria: * A History of a known sensitivity to heparin or ethylene oxide. * A history of hemorrhagic diathesis, bleeding/clotting disorder, thrombocytopenia (defined as platelet count \< 150 x109/L), or for whom the use of heparin would cause excessive or uncontrolled anticoagulation or for whom adequate anticoagulation cannot be safely achieved (ie., hemophilia, recent surgery, acute internal bleeding, gastrointestinal ulcers). * Females who are pr…